Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

Exelixis (EXEL) resumes trading after a long halt, now down 33.4% AH, after announcing it's...

  • Monday, October 31, 2011, 5:52 PM ET
    Exelixis (EXEL) resumes trading after a long halt, now down 33.4% AH, after announcing it's initiating its first phase 3 trial of cabozantinib for patients with a particular type of prostate cancer. Without an agreement with the FDA, the company's not pursuing a special protocol assessment from the agency.
Track new comments on this story

This news story has 2 comments:

  •  
    One should perhaps add that the same drug just tested excellent in another phase III trial. The discrepancies here have something to do with the lack of a good assessment of bone metastasis.
    31 Oct 2011, 06:01 PM Reply Like
  •  
    I did read the press release careful again and have come to the conclusion that this is a overreaction of the market. EXEL did not want to wait longer for a certain endpoint definition by FDA, but went ahead to help those patients with bone metastasis in prostate cancer to live better quality (=pain reduced) lives. I am convinced that the drug will work great as in the other trial and the patients will live longer pain free or reduced. I bought some more at $5 in AH.

    LONG EXEL
    31 Oct 2011, 06:14 PM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »